var data={"title":"Polymyxin B: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polymyxin B: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6802?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polymyxin-b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polymyxin B: Patient drug information&quot;</a> and <a href=\"topic.htm?path=polymyxin-b-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Polymyxin B: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709216\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">When this drug is given IM, IV, or intrathecally, it should be given only to hospitalized patients, so as to provide constant supervision by a physician.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal function should be carefully determined, and patients with renal damage and nitrogen retention should have reduced dosage. Patients with nephrotoxicity due to polymyxin B sulfate usually show albuminuria, cellular casts, and azotemia. Diminishing urine output and a rising blood urea nitrogen (BUN) are indications for discontinuing therapy with this drug.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neurotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurotoxic reactions may be manifested by irritability, weakness, drowsiness, ataxia, perioral paresthesia, numbness of the extremities, and blurring of vision. These are usually associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concurrent therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concurrent or sequential use of other neurotoxic or nephrotoxic drugs with polymyxin B sulfate, particularly bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, and colistin should be avoided.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neuromuscular blockade:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The neurotoxicity of polymyxin B sulfate can result in respiratory paralysis from neuromuscular blockade, especially when the drug is given soon after anesthesia or muscle relaxants.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Use in pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The safety of this drug in human pregnancy has not been established.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211327\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Irrigation;</li>\n      <li>\n        Antibiotic, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211308\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b> Dosing presented as units; 10,000 units = 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS infections: </b>Intrathecal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 50,000 units once daily for 3 to 4 days, then every other day for at least 2 weeks after cultures of the CSF are negative</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing </i>(off-label regimen): Intrathecal, Intraventricular: 50,000 units once daily for 7 days; used in combination with other IV antibiotics (eg, meropenem) (IDSA [Tunkel 2004]; Segal-Maurer 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ocular infections:</b> Ophthalmic: A concentration of 0.1% to 0.25% (10,000 to 25,000 units/mL) is administered as 1 to 3 drops every hour, then increasing the interval as response indicates. A subconjunctival injection of up to 100,000 units/day may be used for <i>P. aeruginosa</i> corneal and conjunctival infections. <b>Note:</b> Avoid total systemic and ophthalmic doses of &gt;25,000 units/kg/<b>day</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic infections: Note:</b> Most of the available limited data evaluating polymyxin B for multidrug resistant pathogens cite manufacturer&rsquo;s labeling dosing of 15,000 to 25,000 units/kg/day IV divided every 12 hours (Furtado 2007; Ouderkirk 2003). More recent publications have cited alternate dosing regimens based on pharmacokinetics/pharmacodynamics data (eg, Monte Carlo simulations) (Sandri 2013a), which support using a loading dose to rapidly achieve target serum concentrations and higher dosing regimens particularly for severe infections (pathogens with an MIC &le;2 mcg/mL); however, actual clinical data employing these higher dosing regimens remain extremely limited. Monitor closely for nephrotoxicity. Dosing based on actual body weight has been suggested for patients within a normal weight range for their height (Kassamali 2015; Pai 2013; Sandri 2013a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 25,000 to 30,000 units/kg/day in divided doses every 4 to 6 hours. <b>Note: </b>Routine IM administration not recommended due to severe pain at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 15,000 to 25,000 units/kg/day in divided doses every 12 hours (maximum: 25,000 units/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i> <b>Infections (eg, intraabdominal infections, pneumonia [hospital-acquired or ventilator-associated], sepsis), due to susceptible multidrug-resistant gram-negative bacilli (eg, </b> <b><i>Pseudomonas aeruginosa,</i></b> <b><i>Acinetobacter spp) </i></b> <b>(off-label dose):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe infections (MIC &le;2 mcg/mL): 25,000 units/kg/dose infused over 2 hours as a one-time loading dose, followed by a maintenance dose of 30,000 units/kg<b>/day</b> divided every 12 hours (Kassamali 2015; Sandri 2013a) <b>or </b>25,000 to 30,000 units/kg<b>/day</b> in 2 divided doses without a loading dose (IDSA [Kalil 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate infections: (MIC &le;1 mcg/mL): 25,000 units/kg<b>/day</b> divided every 12 hours (Sandri 2013a)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Safety data for single doses &gt;30,000 units/kg/dose or for daily doses &gt;2,000,000 units<b>/day</b> are extremely limited. To minimize bacterial regrowth and heteroresistance, consider use in combination with other antibiotics depending on infection site and susceptibilities (Bergen 2015, Kassamali 2015, Rigatto 2015). Monotherapy should <b>only</b> be considered for infections due to carbapenem-resistant organisms (Kassamali 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Obesity: </i>Due to minimal data in morbidly obese patients, consider dosing based on adjusted body weight in these patients (Kassamali 2015; Pai 2013; Sandri 2013a).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalation (off-label route): 500,000 units every 12 hours; an aerosolized beta-2 agonist should be given ~20 minutes prior to polymyxin B (Pereira 2007). <b>Note:</b> Colistimethate sodium is preferred in patients with hospital or ventilator-associated pneumonia (IDSA [Kalil 2016]). In the treatment of pneumonia, concomitant IV administration may also be necessary (Pereira 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Selective gastrointestinal tract decontamination (off-label use):</b> Oral: 1,000,000 units orally 4 times daily for 2 days prior to surgery through post-operative day 3 in combination with oral tobramycin and oral amphotericin B (Roos 2011). <b>Note:</b> To minimize resistance development and preserve polymyxin effectiveness for severe systemic infections, use for selective decontamination is strongly discouraged (Nation 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Obesity: </i>Due to minimal data in morbidly obese patients, consider dosing based on adjusted body weight in these patients (Kassamali 2015; Pai 2013; Sandri 2013a).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211321\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=polymyxin-b-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Polymyxin B: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Dosing presented as units; 10,000 units = 1 mg. Use extra caution with prescribing and/or dispensing. Multiple routes of administration available for use (eg, IV, IM, intrathecal, ophthalmic) and dosing is different based upon route; use extra precaution to verify dose and route of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe, life-threatening, multidrug resistant infection (excluding meningitis): Note:</b>  From experience in adult patients, safety data for single doses &gt;30,000 units/kg/dose or total daily doses &gt;2,000,000 units<b>/day</b> are extremely limited (Kassamali 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 25,000 to 40,000 units/kg/<b>day</b> divided every 4 to 6 hours; <b>Note:</b> Routine IM administration not recommended due to severe pain at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 15,000 to 40,000 units/kg/<b>day</b> divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 25,000 to 30,000 units/kg/<b>day</b> divided every 4 to 6 hours; <b>Note:</b> Routine IM administration not recommended due to severe pain at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Manufacturer's labeling:</i> 15,000 to 25,000 units/kg/<b>day</b> divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Alternate dosing: </i>Children &ge;2 years and Adolescents: Very limited data available: Dosing based on previous recommendations (Hoeprich 1970) and extrapolations from adult pharmacokinetic modeling (Sandri 2013a) which assumes that dosing for pediatric patients &ge;2 years and adults is the same (per current manufacturer's labeling); some centers have used the following:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: 25,000 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: 25,000 to 30,000 units/kg/<b>day</b> divided every 12 hours; consider higher doses for organisms with higher MIC</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis, <i>Pseudomonas aeruginosa</i> or <i>Haemophilus influenzae</i>: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years: Intrathecal: 20,000 units once daily for 3 to 4 days <b>or</b> 25,000 units once every other day; continue 25,000 units once every other day for at least 2 weeks after cultures of the CSF are negative</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years and Adolescents: Intrathecal: 50,000 units daily as a single dose for 3 to 4 days, then every other day for at least 2 weeks after cultures of CSF are negative</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infection (VP-shunt infection, ventriculitis):</b> Limited data available: Children and Adolescents: Intraventricular/intrathecal: 20,000 to 50,000 units/<b>day</b>; lower doses should be used in smaller patients (Hoeprich, 1970; IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ocular infection, </b> <b><i>Pseudomonas aeruginosa:  </i></b>Infants, Children, and Adolescents: Ophthalmic: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211309\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211310\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Manufacturer labeling recommends a dosage reduction in renal impairment however some clinical data suggest that total body clearance of polymyxin B is not altered in renal impairment and that dose adjustment is not necessary (Sandri 2013a; Thamlikitkul 2016). Decreasing daily doses in renal impairment may lead to suboptimal plasma exposure, adverse clinical outcomes and resistance development (Nelson 2015; Sandri 2013a; Zavascki 2008). Some data suggest that non-renal pathways are primarily responsible for elimination. These authors suggest that renal dosage adjustment recommendations should await further data from larger clinical trials (Zavascki 2008). However, use is associated with nephrotoxicity. Recent data suggests polymyxin B undergoes a selective uptake process into renal cells, which plays a primary role in nephrotoxicity potential (Abdelraouf 2014). One small study in patients receiving polymyxin B with a normal baseline renal function observed an overall prevalence rate of nephrotoxicity of 46% with a median onset of 9 days (Dubrovskaya 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer&rsquo;s labeling: </i>IV: For individuals with renal impairment, reduce to dose to &lt;15,000 units/kg/day. More specific dosage reduction not provided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Alternate recommendations:</i> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;80 mL/minute: IV: 15,000 to 25,000 units/kg/day in divided doses every 12 hours (Evans 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 80 mL/minute: IV: Loading dose: 25,000 units/kg on day 1, followed by 10,000 to 15,000 units/kg/day thereafter (Evans 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: IV: Loading dose: 25,000 units/kg on day 1, followed by 10,000 to 15,000 units/kg every 2 to 3 days thereafter (Evans 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anuric patients: IV: Loading dose: 25,000 units/kg on day 1, followed by 10,000 units/kg every 5 to 7 days thereafter (Evans 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis, peritoneal dialysis: IM: 250,000 units every 24 hours; no supplemental dose necessary (Cunha 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVHD: No dosage adjustment necessary (Sandri 2013b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858538\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49016066\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211287\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500,000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211272\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211290\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IM:</b> The IM route is not routinely recommended due to severe pain at injection site. Intramuscular injections should only be administered in a hospital.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV:</b> Administer as a continuous IV infusion or in divided doses every 12 hours. Administration over 60 to 120 minutes as an intermittent infusion has been reported (Teng 2008; Zavascki 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Inhalation for nebulization</b> (off-label use/route): Use with standard jet nebulizer connected to an air compressor; an aerosolized beta-2 agonist should be given ~20 minutes prior to polymyxin (Pereira 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intrathecal:</b> May be administered intrathecally; intrathecal injections should only be administered in a hospital.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic:</b> May be administered as a subconjunctival injection or as topical ophthalmic drops.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211289\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infections, acute:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pseudomonal infections:</b> Treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of <i>Pseudomonas aeruginosa</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Serious infections:</b> Treatment of serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: <i>H. influenzae</i>, specifically meningeal infections; <i>Escherichia coli</i>, specifically urinary tract infections; <i>Aerobacter aerogenes</i>, specifically bacteremia; <i>Klebsiella pneumoniae</i>, specifically bacteremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In meningeal infections, polymyxin B sulfate should be administered only by the intrathecal route.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470829\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Selective gastrointestinal tract decontamination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5977966\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211279\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Facial flushing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Neurotoxicity (includes ataxia, blurred vision, drowsiness, irritability, numbness of extremities oral paresthesia), dizziness, drug fever, meningitis (intrathecal administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypocalcemia, hypochloremia, hypokalemia, hyponatremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Nephrotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Neuromuscular blockade, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211293\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to polymyxin B or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211276\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local reactions: May cause severe pain at IM injection site or thrombophlebitis at IV infusion site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: <b>[US Boxed Warning]: May cause nephrotoxicity; avoid concurrent or sequential use of other nephrotoxic drugs.</b> Usual risk factors include preexisting renal impairment, advanced age and dehydration. Polymyxin B-induced nephrotoxicity may be manifested by albuminuria, cellular casts, and azotemia; monitor BUN, serum creatinine, and urinary analysis at baseline and as clinically indicated. Discontinue therapy with decreasing urinary output and increasing BUN. Data suggest polymyxin B undergoes a selective uptake process into renal cells, which plays a primary role in nephrotoxicity potential (Abdelraouf 2014). One small study in patients receiving polymyxin B with a normal baseline renal function observed an overall prevalence rate of nephrotoxicity of 46% with a median onset of 9 days (Dubrovaskaya 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity, which can also result in respiratory paralysis from neuromuscular blockade especially when the drug is given soon after anesthesia or muscle relaxants. Avoid concurrent or sequential use of other neurotoxic drugs.</b> Avoid concurrent use of curariform muscle relaxants and other neurotoxic drugs (eg, ether, tubocurarine, succinylcholine, gallamine, decamethonium, sodium citrate), which may cause respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with impaired renal function; manufacturer&rsquo;s prescribing information states dosage reduction required, however, recent pharmacokinetic/pharmacodynamic and clinical studies suggest daily dose requirement is not affected by renal function (Sandri 2013a; Nelson 2015; Thamlikitkul 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Safety in pregnant women not established.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IM/Intrathecal/IV administration: <b>[US Boxed Warning]:  Intramuscular/intrathecal/intravenous administration only to hospitalized patients.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parenteral administration: Polymyxin B sulfate is most toxic when given parenterally; avoid parenteral use whenever possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299903\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211281\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9790&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): Polymyxin B may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Polymyxin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Polymyxin B may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Polymyxin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211295\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Safety in pregnant women has not been established.</b> Animal reproduction studies are lacking. A teratogenic potential has not been identified for polymyxin b, but very limited data is available (Heinonen 1977; Kazy 2005). Based on the relative toxicity compared to other antibiotics, systemic use in pregnancy is not recommended (Knothe 1985). Due to poor tissue diffusion, topical use would be expected to have only minimal risk to the mother or fetus (Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7306030\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if polymyxin b is excreted in human milk. If present in breast milk, polymyxin b is not absorbed well from a normal gastrointestinal tract. Nondose-related effects could include modification of the bowel flora. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211285\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Neurologic symptoms and signs of superinfection; renal function (decreasing urine output and increasing BUN may require discontinuance of therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211288\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Serum concentrations &gt;5 mcg/mL are toxic in adults (Hoeprich 1970)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211275\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to phospholipids, alters permeability, and damages the bacterial cytoplasmic membrane permitting leakage of intracellular constituents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211292\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not absorbed from GI tract.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Tissue diffusion is poor; critically ill patients: Central V<sub>d</sub>: ~0.09 L/kg; peripheral V<sub>d</sub>: 0.33 L/kg (Sandri 2013a); does not cross blood brain barrier into CSF or into the eye (Hoeprich 1970)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~60% (Kassamali 2015); 79% to 92% (critically ill patients) (Zavascki 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 6 hours, increased with reduced renal function (Evans 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: Within 2 hours (Hoeprich 1970)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;1% as unchanged drug within first 12 hours; as therapy continues, up to 60% as unchanged drug in the urine [Evans 1999]); Critically ill adults: Urine (median: 4% [range: 0.98% to 17.4%] as unchanged drug) (Sandri 2013a)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323703\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Polymyxin B Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500000 unit (1): $6.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539915\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aerosporin (IN);</li>\n      <li>Alosol (MX);</li>\n      <li>Biodexan Ofteno (MX);</li>\n      <li>Cortisporin Otico (MX);</li>\n      <li>Dexsul (MX);</li>\n      <li>Glubacida (MX);</li>\n      <li>Isopto-Biotic (SE);</li>\n      <li>Maxitrol (MX);</li>\n      <li>Neobacigrin (MX);</li>\n      <li>Neosporin (MX);</li>\n      <li>Polixin (MX);</li>\n      <li>Poly-MXB (PH);</li>\n      <li>Polymyxin B Pfizer (DE);</li>\n      <li>Polymyxine B FNA (NL);</li>\n      <li>Septilisin (MX);</li>\n      <li>Synalar (MX);</li>\n      <li>Syntex (MX);</li>\n      <li>Tribiot (MX);</li>\n      <li>Trioft&iacute;n (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24733472\"></a>Abdelraouf K, Chang KT, Yin T, et al. Uptake of polymyxin B into renal cells. <i>Antimicrob Agents Chemother</i>. 2014;58(7):4200-4202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/24733472/pubmed\" target=\"_blank\" id=\"24733472\">24733472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. <i>Pharmacotherapy</i>. 2015;35(1):34-42. doi: 10.1002/phar.1537.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25630411/pubmed\" target=\"_blank\" id=\"25630411\">25630411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunha BA, Friedman PE. Antibiotic dosing in patients with renal insufficiency or receiving dialysis. <i>Heart Lung</i>. 1988;17(6,pt 1):612-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/3056882/pubmed\" target=\"_blank\" id=\"3056882\">3056882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25652747\"></a>Dubrovskaya Y, Prasad N, Lee Y, et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. <i>J Antimicrob Chemother</i>. 2015;70(6):1903-1907.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25652747/pubmed\" target=\"_blank\" id=\"25652747\">25652747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. <i>Ann Pharmacother</i>. 1999;33(9):960-967.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/10492501/pubmed\" target=\"_blank\" id=\"10492501\">10492501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant <i>Pseudomonas aeruginosa</i>. <i>Int J Antimicrob Agents</i>. 2007;30(4):315-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/17631984/pubmed\" target=\"_blank\" id=\"17631984\">17631984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinonen OP, Slone D, and Shapiro S, &quot;Birth Defects and Drugs in Pregnancy,&quot; Publishing Sciences Group, Inc, Littleton, MA, 1977.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoeprich PD, &ldquo;The Polymyxins,&rdquo; <i>Med Clin North Am</i>, 1970, 54(5):1257-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/4319624/pubmed\" target=\"_blank\" id=\"4319624\">4319624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horton J and Pankey GA, &ldquo;Polymyxin B, Colistin, and Sodium Colistimethate,&rdquo; <i>Med Clin North Am</i>, 1982, 66(1):135-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/6278236/pubmed\" target=\"_blank\" id=\"6278236\">6278236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kassamali Z, Jain R, Danziger LH. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics. <i>Int J Infect Dis</i>. 2015;30:125-132. doi: 10.1016/j.ijid.2014.10.014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25461655/pubmed\" target=\"_blank\" id=\"25461655\">25461655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kazy Z, Puh&oacute; E, and Czeizel AE, &quot;Parenteral Polymyxin B Treatment During Pregnancy,&quot; <i>Reprod Toxicol</i>, 2005, 20(2):181-2<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/15907651/pubmed\" target=\"_blank\" id=\"15907651\">15907651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knothe H and Dette GA, &quot;Antibiotics in Pregnancy: Toxicity and Teratogenicity,&quot; <i>Infection</i>, 1985, 13(2):49-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/2987132/pubmed\" target=\"_blank\" id=\"2987132\">2987132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25459221\"></a>Nation RL, Li J, Cars O, Couet W, Dudley MN, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. <i>Lancet Infect Dis</i>. 2015;15(2):225-234. doi: 10.1016/S1473-3099(14)70850-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25459221/pubmed\" target=\"_blank\" id=\"25459221\">25459221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. <i>Antimicrob Agents Chemother</i>. 2015;59(11):7000-7006. doi: 10.1128/AAC.00844-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/26324272/pubmed\" target=\"_blank\" id=\"26324272\">26324272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. <i>Antimicrob Agents Chemother</i>. 2003;47(8):2659-2562.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/12878536/pubmed\" target=\"_blank\" id=\"12878536\">12878536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pai MP. Polymyxin B dosing in obese and underweight adults. <i>Clin Infect Dis</i>.2013;57(12):1785. doi: 10.1093/cid/cit604.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/24051863/pubmed\" target=\"_blank\" id=\"24051863\">24051863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. <i>Diagn Microbiol Infect Dis</i>. 2007;58(2):235-240. doi: 10.1016/j.diagmicrobio.2007.01.008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/17350201/pubmed\" target=\"_blank\" id=\"17350201\">17350201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polymyxin B for Injection [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals, Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rigatto MH, Vieira FJ, Antochevis LC, Behle TF, Lopes NT, Zavascki AP. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with <i>Acinetobacter baumannii</i> or <i>Pseudomonas aeruginosa</i> infections.<i> Antimicrob Agents Chemother</i>. 2015;59(10):6575-6580. doi: 10.1128/AAC.00494-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/26259799/pubmed\" target=\"_blank\" id=\"26259799\">26259799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21751181\"></a>Roos D, Dijksman LM, Oudemans-van Straaten HM, et al, &ldquo;Randomized Clinical Trial of Perioperative Selective Decontamination of the Digestive Tract versus Placebo in Elective Gastrointestinal Surgery,&rdquo; <i>Brit J Surg</i>, 2011, 98(10):1365&ndash;72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/21751181/pubmed\" target=\"_blank\" id=\"21751181\">21751181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. <i>Clin Infect Dis</i>. 2013;57(4):524-531. [Sandri 2013a]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/23697744/pubmed\" target=\"_blank\" id=\"23697744\">23697744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG,et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. <i>J Antimicrob Chemother</i>. 2013;68(3):674-677. doi: 10.1093/jac/dks437. [Sandri 2013b]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/23179561/pubmed\" target=\"_blank\" id=\"23179561\">23179561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Segal-Maurer S, Mariano N, Qavi A, Urban C, Rahal JJ Jr. Successful treatment of ceftazidime-resistant <i>Klebsiella pneumoniae</i> ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. <i>Clin Infect Dis</i>. 1999;28(5):1134-1138. doi: 10.1086/514754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/10452648/pubmed\" target=\"_blank\" id=\"10452648\">10452648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistantGram-negative respiratory tract infections. <i>J Antimicrob Chemother.</i> 2004;54(2):566-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/15269195/pubmed\" target=\"_blank\" id=\"15269195\">15269195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teng CB, Koh PT, Lye DC, Ang BS. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. <i>Int J Antimicrob Agents</i>. 2008;31(1):80-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/17920246/pubmed\" target=\"_blank\" id=\"17920246\">17920246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, et al. Dosing and pharmacokinetics of polymyxin B in renal insufficiency. <i>Antimicrob Agents Chemother</i>. 2016. doi: 10.1128/AAC.01337-16<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/27799209/pubmed\" target=\"_blank\" id=\"27799209\">27799209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284. doi: 10.1086/425368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zavascki AP, Goldani LZ, Cao G, et al, &ldquo;Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients,&rdquo; <i>Clin Infect Dis</i>, 2008, 47(10):1298-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/18840079/pubmed\" target=\"_blank\" id=\"18840079\">18840079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment ofmultidrug-resistant pathogens: a critical review. <i>J Antimicrob Chemother</i>. 2007;60(6):1206-1215.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/17878146/pubmed\" target=\"_blank\" id=\"17878146\">17878146</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9790 Version 131.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709216\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F211327\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F211308\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F211321\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F211309\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F211310\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20858538\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F49016066\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211287\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F211272\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F211290\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F211289\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470829\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5977966\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211279\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211293\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211276\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299903\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F211281\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F211295\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7306030\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F211285\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F211288\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211275\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F211292\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323703\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539915\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9790|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polymyxin-b-patient-drug-information\" class=\"drug drug_patient\">Polymyxin B: Patient drug information</a></li><li><a href=\"topic.htm?path=polymyxin-b-pediatric-drug-information\" class=\"drug drug_pediatric\">Polymyxin B: Pediatric drug information</a></li></ul></div></div>","javascript":null}